Abeona Therapeutics Inc (NASDAQ:ABEO) has been assigned a consensus rating of “Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $28.50.
A number of equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 target price (up previously from $20.00) on shares of Abeona Therapeutics in a research note on Monday, October 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 target price on shares of Abeona Therapeutics in a research note on Friday, October 6th. SunTrust Banks assumed coverage on Abeona Therapeutics in a research note on Wednesday, November 8th. They issued a “buy” rating and a $26.00 target price for the company. Zacks Investment Research raised Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Wednesday, November 22nd. Finally, Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, November 20th.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down $0.15 during mid-day trading on Tuesday, reaching $15.70. The company’s stock had a trading volume of 364,100 shares, compared to its average volume of 550,756. Abeona Therapeutics has a 52-week low of $4.50 and a 52-week high of $22.75. The company has a market capitalization of $734.37, a price-to-earnings ratio of -24.15 and a beta of 2.34.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.22 million. research analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in Abeona Therapeutics by 138.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 99,996 shares of the biopharmaceutical company’s stock valued at $640,000 after purchasing an additional 58,067 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $264,000. Northern Trust Corp raised its position in Abeona Therapeutics by 406.3% during the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 206,775 shares during the last quarter. TIAA CREF Investment Management LLC bought a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $430,000. Finally, Family Management Corp raised its position in Abeona Therapeutics by 50.0% during the 3rd quarter. Family Management Corp now owns 36,000 shares of the biopharmaceutical company’s stock valued at $614,000 after purchasing an additional 12,000 shares during the last quarter. 41.95% of the stock is owned by institutional investors.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.